Fly Intel: Top five analyst initiations » 10:1007/1507/15/20
LVGO, TALO, WDC, STX, SAM, PROG
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Livongo Health (LVGO) initiated with an Outperform at Credit Suisse. 2. Talos Energy (TALO) initiated with a Buy at Stifel. 3. Western Digital (WDC) was initiated with an Outperform at Bernstein while Seagate (STX) was initiated with a Market Perform. 4. Boston Beer (SAM) initiated with an Outperform at Evercore ISI. 5. Progenity (PROG) initiated with an Outperform at Baird and Raymond James and an Overweight at Wells Fargo and Piper Sandler. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Fly Intel: After-Hours Movers » 19:0007/1407/14/20
LCII, MRNA, LVGO, PVH, VNOM, TALO, GSK, KRUS, ZYXI, ADPT
Livongo Health Founder: We work hand in hand with Teladoc » 18:2207/1407/14/20
In an interview on…
In an interview on CNBC's Mad Money, Glen Tullman said he expects many more companies to move to Livongo in the near future. Employers are doubling down on Livongo to keep employees productive and healthy, according to Tullman. Telehealth is one-on-one, but Livongo takes it to the next level, he noted.
Livongo Health initiated with an Outperform at Credit Suisse » 16:0907/1407/14/20
Credit Suisse analyst…
Credit Suisse analyst Jailendra Singh initiated coverage of Livongo Health with an Outperform rating and $132 price target. The company operates in a "highly underpenetrated and growing" chronic care market, Singh tells investors in a research note. The analyst believes Livongo is "barely scratching the surface" in a market which the company sizes at $46.7B. This estimate is conservative as Livongo uses chronic disease prevalence and population estimates using 2015 data, which have moved exponentially higher today, says Singh. The analyst also sees "several other areas" of chronic care management that are largely underpenetrated where Livongo has yet to enter.
UnitedHealth's new diabetes service not seen impacting Livongo near-term » 12:1207/1407/14/20
LVGO, UNH, TDOC, HCAT, CHNG
Shares of Livongo Health…
UnitedHealth competition won't impact Livongo near term, says KeyBanc » 08:3207/1407/14/20
KeyBanc analyst Donald…
KeyBanc analyst Donald Hooker reiterates an Overweight rating on Livongo Health (LVGO) with a $105 price target after UnitedHealth (UNH) yesterday launched a competitive digital diabetes service. The stock closed yesterday down 8%, or $8.30, to $97.38. The analyst does not expect any impact to Livongo's near-term results, noting that UnitedHealth is not a channel partner. Also, it appears that UnitedHealth's new diabetes service will be "channel-limited" to its own client base, Hooker tells investors in a research note titled "Imitation Is the Greatest Form of Flattery." Further, Livongo to date has demonstrated high client retention of 94%, adds the analyst. In a "bull-case" scenario, he sees UnitedHealth's entry into the digital diabetes space as an accelerant for Livongo. The move could put competitive pressure on regional Blues and other health plans to more aggressively feature their own digital diabetes solution, says Hooker. In a "bear-case" scenario, UnitedHealth's Level2 launch could make it more difficult for Livongo to prospect within UnitedHealth's small- and mid-sized employer client base, notes the analyst.
Livongo Health initiated with a Buy at Citi » 07:1807/1407/14/20
Citi analyst Daniel…
Citi analyst Daniel Grosslight initiated coverage of Livongo Health (LVGO) with a Buy rating and $125 price target. The analyst rolled out coverage of the healthcare technology sector with a positive bias. A new era of healthcare technology investing has emerged, and the healthcare ecosystem is on verge of its "Netflix moment," Grosslight tells investors in a research note. The analyst favors companies with interoperable platforms, omni-channel distribution and strong relationships with patient aggregators. His top picks for investors looking for "SMID-cap growth and disruption" are Teladoc Health (TDOC) and Health Catalyst (HCAT). For investors looking for value, Grosslight's top pick is Change Healthcare (CHNG).
|Over a week ago|
Livongo Health price target raised to $110 from $69 at Canaccord » 07:3607/0907/09/20
Canaccord analyst Richard…
Canaccord analyst Richard Close raised the firm's price target on Livongo Health to $110 from $69 and keeps a Buy rating on the shares. The price target increase reflects the positive Q2 preannouncement which suggests the company continues to outperform and execute on its business plan with strong customer launches year-to-date, improved enrollment and retention, and impressive upside to revenues versus guidance.
Livongo Health price target raised to $120 from $53 at RBC Capital » 09:1107/0807/08/20
RBC Capital analyst Sean…
RBC Capital analyst Sean Dodge raised the firm's price target on Livongo Health to $120 from $53 and keeps an Outperform rating on the shares. The analyst is citing the company's "significant" total addressable market and his expectation for continued revenue growth at a "blistering" pace of 60%-65% over the next two years. Dodge adds that Livongo's "AI+AI engine/service delivery" is also "increasingly scalable."
Livongo Health price target raised to $120 from $70 at Needham » 07:3007/0807/08/20
Needham analyst Scott…
Needham analyst Scott Berg raised the firm's price target on Livongo Health to $120 from $70 and keeps a Buy rating on the shares after the company raised its Q2 revenue guidance yesterday. The outlook was driven by a combination of faster-than-expected new member additions and lower-than-modeled churn, the analyst tells investors in a research note, stating that churn had been modeled "conservatively" due to the COVID-19 uncertainty. Berg adds that Livongo is in a hyper-growth phase and that its stock "should be valued above the upper end of the historical peer-group range."